DARIUS-JEAN NAMDJOU, Head of Regulatory Affairs & Pharmacovigilance, Immunic Therapeutics

Dr. Darius-Jean Namdjou graduated as Ph.D. chemist from Aachen University, Germany, in 2006. After a two year Post-Doc stay at the National Research Council in Ottawa, Canada and further professional training, Darius joined the headquarter of Grünenthal GmbH, Aachen, Germany as Regulatory Affairs Manager in 2009. Darius gathered two years experience with the coordination of marketing authorization and lifecycle activities in emerging and further RoW markets, covering the product portfolio of Grünenthal. Since August 2011, Darius lead Regulatory Affairs product teams, on a global level, for several of Grünenthal’sdevelopment and established pain products. He further specialized himself on the Regulatory Affairs part of Due Diligence projects.

Since March 2021, Darius took on a new challenge by joining the clinical stage biotech company Immunic AG in Munich, Germany, specialized in autoimmune and inflammatory diseases. Darius leads the Regulatory Affairs and Pharmacovigilance team for the company. In this role,he is currently further building up the team, respective internal functional structures to support the development of the company’s compounds, while also managing and further strengthening the relationship to vendors specialized in the Regulatory Affairs and Pharmacovigilance field.

Darius is a member of the Drug Information Association (DIA), German Society for Regulatory Affairs (DGRA) and the Regulatory Affairs group of BioDeutschland. He is also a member of the Regulatory Affairs Professional Society (RAPS), where he serves on the Membership Commitee. Darius is a regular speaker at conferences and a lecturer in Regulatory Affairs for the University of Duisburg-Essen (UDE).